How do we manufacture clinical‐grade interleukin‐15–stimulated natural killer cell products for cancer treatment?-Reference-Cited by-同舟云学术

How do we manufacture clinical‐grade interleukin‐15–stimulated natural killer cell products for cancer treatment?

Published:2018-03-14 Issue:6 Volume:58 Page:1340-1347
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Fernández Lucía¹,Leivas Alejandra²,Valentín Jaime³,Escudero Adela⁴,Corral Dolores⁵,de Paz Raquel⁶,Vela Maria³,Bueno David⁷,Rodríguez Rebeca⁸,Torres Juan Manuel⁸,Díaz‐Almirón Mariana⁹,López‐Collazo Eduardo³,Martinez‐Lopez Joaquin²^ORCID,Pérez‐Martínez Antonio⁷

Affiliation:

1. Clinical Research DepartmentSpanish National Cancer Research Center, CNIO

2. Hematology DepartmentUniversity Hospital 12 de Octubre

3. Tumor Immunology Lab, IdiPAZ

4. Medical and Molecular Genetics Institute, INGEMM

5. Pediatric DepartmentAutonomous University of Madrid

6. Hematology Department

7. Pediatric Hemato‐Oncology

8. Immunology Department

9. Biostatistics DepartmentLa Paz University HospitalMadrid Spain

Funder

Instituto de Salud Carlos III

Federación Española de Enfermedades Raras

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.14573

Reference19 articles.

1. Use of allogeneic NK cells for cancer immunotherapy

2. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 reveals intrinsic functional plasticity

3. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation

4. Interleukin‐18 (IL‐18) synergizes with IL‐2 to enhance cytotoxicity, interferon‐gamma production, and expansion of natural killer cells;Son YI;Cancer Res,2001

5. A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia;Journal of Translational Medicine;2024-03-13

2. Manufacturing CAR-NK against tumors: Who is the ideal supplier?;Chinese Journal of Cancer Research;2024

3. Clinical grade production of IL ‐15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post‐transplant cyclophosphamide;Transfusion;2022-01-13

4. Advances in NK cell production;Cellular & Molecular Immunology;2022-01-05

5. Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy;Immunology;2021-12-02